Daewoong Pharmaceutical said on the 2nd that osteoporosis drug Stovoclo posted 11.8 billion won in sales in its first year on the market. Stovoclo is a biosimilar of Prolia and is co-marketed by Daewoong Pharmaceutical and Celltrion Pharm.
A single injection of Stovoclo maintains its effect for six months. Other drugs must be taken daily or administered every one week to three months. The company said it reduces the number of hospital visits for patients and eases the burden of medication management for medical staff.
The price of Stovoclo is 100,000 won, about half that of the original drug (200,000 won). The expense patients actually bear averages 5,400 won per month. Stovoclo is prescribed at about 50 general and university hospitals nationwide. The company set a goal of achieving 100 billion won in annual sales.
Park Hyeong-cheol, head of the prescription drug (ETC) marketing division at Daewoong Pharmaceutical, said, "We will help more osteoporosis patients receive treatment based on an economical price and an excellent product."